Asia's #1 Pediatric HSCT Center · 900+ Annual Transplants · 14-Day Donor Identification
Led by Professor Sun Yuan, Hospital Director and Head of Hematology-Oncology, and Professor Wu Minyuan, distinguished expert with State Council Special Contribution, our department is one of China's leading centers for childhood blood disorders.
Our comprehensive treatment system features:
Parents or relatives with only 50% HLA compatibility can serve as donors. Our groundbreaking research on modified haploidentical transplantation pretreatment for primary HLH achieved a 2-year overall survival rate of 78.4% and 5-year rate of 73.7%.
Acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and relapsed/refractory cases. Cure rates from 80% to 90% for specific subtypes.
Primary and secondary HLH with groundbreaking treatment protocols. Modified haploidentical transplant achieving industry-leading survival rates.
Aplastic anemia, myelodysplastic syndrome, and other bone marrow failure diseases with comprehensive diagnostic and treatment approaches.
Comprehensive thalassemia treatment including stem cell transplantation as curative therapy. Expert in both matched and haploidentical transplants.
Diagnosis and treatment of primary immunodeficiency disorders with stem cell transplant as definitive therapy for eligible patients.
Comprehensive treatment revolution for neuroblastoma combining surgery, chemotherapy, stem cell transplant, and immunotherapy.
Chimeric Antigen Receptor T-cell therapy for relapsed/refractory B-cell leukemia and lymphoma. Cutting-edge immunotherapy offering hope when conventional treatments fail.
Cytokine-Induced Killer cells and Natural Killer cell therapies providing additional treatment options for blood cancers, particularly in combination with transplantation.
Advanced cord blood transplant technology with the "Square of Life" approach. Effective for patients without matched sibling or unrelated donors.
Precision medicine approach using gene sequencing for diagnosis and targeted therapy for specific genetic mutations in blood disorders and rare diseases.